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antipsychotic-stimulant group. No statistically significant difference was found in 
the risk of cardiovascular events among patients with mood stabilizer-stimulant 
combination (HR= 0.98, 95% Confidence Interval, 95% CI: 0.49-1.99) or antipsy-
chotic-stimulant combination (HR= 0.57, 95% CI: 0.31-1.05) compared to stimulant 
monotherapy. ConClusions: The current study did not find any difference in the 
cardiovascular risk after addition of mood stabilizer or atypical antipsychotic to 
stimulant monotherapy in patients with ADHD and bipolar disorder. More studies 
are needed to evaluate overall safety profiles of these therapeutic combinations in 
patients with comorbid ADHD and bipolar disorder.
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DisContinuation of statin use after HemoDialysis anD tHe risk of 
CarDioVasCular Diseases
Liu Y.1, Huang W.1, Chang W.1, Wen Y.2, Tsai Y.1
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objeCtives: Clinical trials showed insignificant effects of statins on preventing car-
diovascular diseases(CVD) among hemodialysis patients. This study is to examine the 
association between discontinuation of statin use after hemodialysis and the risk of 
CVD. Methods: We conducted a population-based retrospective cohort study using 
year 1997-2008 National Health Insurance Research Database. We selected patients 
who are 20 years old or above and first time receiving maintenance hemodialysis. 
The selected patients were also those prescribed statins at least once in the 180 
days before the first hemodialysis. We excluded the patients who had medical his-
tory of kidney transplantation or maintenance peritoneal dialysis. Continuous use 
of statins was defined as receiving prescriptions of statins in the first 90 days after 
hemodialysis. We used the Cox proportional hazards model to analyze the associa-
tion between the discontinuation status and the risk of hospitalization or surgeries 
for coronary heart diseases (CHD) and non-hemorrhagic stroke. The propensity score 
method was used to adjust the self-selection bias in the statin user and non-user 
groups. Results: Among 8,949 patients examined, 2,079 (23.2%) patients used statins 
in the first 90 days after hemodialysis. After adjusted by the propensity score, the Cox 
model showed discontinuation of statin use in the first 90 days after dialysis was not 
associated with higher risk of hospitalization or surgeries for CHD and non-hem-
orrhagic stroke (HR 0.55ï¿½, 95% CI 0.50, 0.61) compared to statin users. The results 
were consistent when stratifying the patients into those with medical history of CVD 
(n= 5288, HR 0.53ï¿½, 95% CI 0.47, 0.60) and those without (n= 3661, HR 0.61, 95% CI 
0.50, 0.74). ConClusions: Discontinuation of statin use after hemodialysis does not 
increase the risk of hospitalization or surgeries for CHD and non-hemorrhagic stroke. 
However, this result cannot rule out the possible association between the severity of 
hypercholesterolemia or predicted risk of CVD and statin use.
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objeCtives: A novel genotype-guided personalized warfarin dosing (PGx) service 
was implemented at the University of Illinois Hospital & Health Sciences System. 
The aim of this study was to examine the impact of race on the association between 
the (PGx) service and anticoagulation related clinical outcomes. Methods: 
Multivariate linear, logistic, and survival models were used to examine differences 
across race in the association between the PGx service and several clinical outcomes. 
These models were adjusted for confounders, and inverse probability treatment 
weight propensity scoring was used. Our primary outcome of interest was time to 
first therapeutic INR. Results: A total of 339 patients managed by the PGx service 
(mean age 56±16 years; 61% African-American; 55% female) and 299 historical con-
trols (mean age 54±16 years; 74% African-American, 64% female) were included. 
In our primary outcome, the treatment effect in time to first therapeutic INR was 
significantly higher in African-Americans compared to Caucasians (HR: 1.86, 95%CI: 
1.3, 2.8 vs. HR: 1.24, 95%CI: 0.4, 3.8, respectively). The treatment effect in time in 
therapeutic international normalized ratio (INR) range was significantly higher in 
African-Americans than in Caucasians over the initial 7 days of therapy (β : 5.52 
days, 95% CI: 1.4, 9.6 vs. β : 0.78, 95%CI: -9.3, 10.8, respectively). The treatment effect 
in proportion of INRs at extremes (< 1.5 and > 4) was lower in African-Americans 
compared to Caucasians (β : -25.56, 95% CI: -31.6, -19.6 vs. β : -22.46, 95% CI: -36.8, 
-8.2, respectively). Additionally, relative to Caucasians, African-Americans in the PGx 
group were 2.17 times more likely to have an INR in therapeutic range at discharge 
(OR: 2.17, 95% CI: 1.0, 4.7). ConClusions: A novel genotype-guided personalized 
warfarin service was positively associated with anticoagulation related clinical out-
comes, and this association was stronger in African-American patients.
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objeCtives: eHealth is the transfer of health resources, care, and data by electronic 
means and has the potential to promote reductions in the cost of care. It has been 
employed by medical professionals to manage chronic diseases outside of a clinical 
setting, provide useful data for decision making, and deliver timely information and 
care to the patient. This review assesses the use of eHealth programs in chronic 
disease management and identifies the settings and patient populations that have 
resulted in successful outcomes. Methods: A systematic literature review was 
conducted in Embase, Medline, CINAHL, and PsycINFO. Inclusion criteria were 
English language studies since 2005 evaluating the efficacy of an eHealth program 
on patients with chronic disease(s). Studies in which e-mail communication was 
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ComParatiVe effeCtiVeness of riVaroxaBan anD stanDarD 
antiCoaGulant tHeraPies for PreVention of Primary Venous 
tHromBoemBolism in Patients unDerGoinG major ortHoPeDiC 
surGery
Shewale A.R., Martin B.C.
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objeCtives: Venous thromboembolism (VTE) is one of the major complications 
after major orthopedic surgeries (MOS). In 2011, FDA approved rivaroxaban for VTE 
prevention among patients undergoing MOS. The aim of our study is to empirically 
evaluate the comparative effectiveness of rivaroxaban, warfarin, and low molecu-
lar weight heparins (LMWHs) for VTE prevention among MOS patients using “real 
world” data. Methods: A cohort study using IMS Lifelink Plus (2006-2013) data 
compared the risk of VTE and major bleed events among MOS patients exposed 
to rivaroxaban, warfarin, LMWHs, or fondaparinux with those who are not anti-
coagulated within 7 days after their MOS-hospital discharge. Kaplan Meier curves 
and Cox proportional hazard models were used to assess the risk of VTE and major 
bleed events and to adjust for potential confounders. Results: A cohort of 35,279 
MOS were included which provided 68,340 person years of follow up including 1,004 
rivaroxaban, 7,339 warfarin, 5,692 LMWH, 841 fondaparinux exposed patients and 
20,403 patients who did not receive an initial anticoagulant. Risk of VTE was low-
est for rivaroxaban (H.R.= 0.282; 95%CI:0.156-0.510) followed LMWHs (H.R.= 0.671 
[95%CI= 0.582-0.773]), fondaparinux (H.R.= 0.680 [95%CI = 0.485-0.951]) and warfa-
rin (H.R.= 0.872 [95%CI= 0.778-0.978]) when compared to no anticoagulant use in 
unadjusted cox models. After adjusting for potential confounders, only rivaroxaban 
(H.R.= 0.395 [95%CI= 0.215-0.742]) and LMWHs (H.R.= 0.755[95%CI= 0.643-0.873]) sig-
nificantly reduced the risk of VTE. However, these results were not significant in 
a sensitivity analysis using a more strict definition to detect VTEs in claims data. 
There were no bleed events for rivaroxaban users and the risk of bleed events were 
not significantly different among anticoagulants and non-anticoagulant exposure 
in both the adjusted and the unadjusted models. ConClusions: LMWHs and 
Rivaroxaban were associated with reduced VTE events and no detectable increase 
in major bleeds among MOS patients. These findings, particularly those on major 
bleed events, should be confirmed in larger study populations.
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objeCtives: This analysis aimed to assess the potential clinical risk/benefits associ-
ated with the lifetime use of apixaban versus edoxaban in patients with non-valvular 
atrial fibrillation (NVAF) in the United States (US). Methods: A Markov model was 
developed to extrapolate the observed clinical impact of apixaban versus a regimen 
of edoxaban starting at 60 mg at the lifetime horizon. Outcomes assessed included 
the number of clinical events avoided for every 1000 patients treated, number of 
patients needed to treat to prevent one stroke, and number of patients needed to 
harm with an additional major bleed. Key sources of inputs used to populate the 
model included: indirect comparison data versus edoxaban from published blinded 
randomized trials vs warfarin; US life tables for life expectancy; published literature 
for increased mortality related to outcome events modeled. Results: In a cohort of 
1,000 patients, treatment with apixaban (at doses used in clinical trials) in comparison 
with edoxaban 60 mg resulted in 6 fewer strokes and caused 10 fewer major bleeds 
over the average projected lifetime. This translated in 172 patients needed to treat 
with apixaban versus edoxaban 60 mg to prevent one stroke with no additional major 
bleeding. The reduction in clinical events resulted in 29 additional discounted life-
years for the cohort of 1,000 patients treated with apixaban. ConClusions: Using an 
indirect comparison, lifetime use of apixaban is projected to increase life-expectancy 
versus edoxaban 60 mg QD in the US. It also appears to provide dual risk reduction 
based on efficacy and safety benefits versus edoxaban 60 mg starting regimen.
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CarDioVasCular safety witH tHe ConCurrent use of mooD 
staBilizers or atyPiCal antiPsyCHotiCs anD stimulants in CHilDren 
anD aDolesCents witH attention DefiCit/HyPeraCtiVity DisorDer 
anD BiPolar DisorDer
Rane P., Bali V., Aparasu R.R.
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objeCtives: This study compared the cardiovascular safety of the addition of mood 
stabilizers or atypical antipsychotics to stimulant monotherapy in children and ado-
lescents diagnosed with ADHD and bipolar disorder. Methods: This retrospective 
cohort study used 2004-2007 IMS LifeLink™ Health Plan Claims Database. Children 
and adolescents aged 6 to 17 years diagnosed with ADHD and bipolar disorder who 
initiated a new treatment with stimulants were followed for 12 months to compare 
the safety of addition of mood stabilizers or atypical antipsychotics to stimulant 
monotherapy. Only patients who had continuous eligibility 6 months before and 12 
months after the index stimulant date were selected. Exposure to a mood stabilizer 
or atypical antipsychotic agent after the initiation of the index stimulant treatment 
formed the primary exposure. The primary outcome was defined as the first hospi-
talization or emergency room (ER) visit for cardiovascular disorder identified using 
International Classification of Diseases- 9th Revision, Clinical Modification (ICD-9 
CM) codes. Cardiovascular risk was compared using time-varying Cox regression 
analysis adjusting for other cardiac risk factors. Results: Of the 1,769 ADHD and 
bipolar patients, 48.28% were prescribed stimulants only, 16.68% were on mood 
stabilizer-stimulant combination and 35.05% were on antipsychotic-stimulant 
combination therapy. The incidence of cardiovascular events were 5.15% in the 
stimulants-only group, 4.75% in the mood stabilizer-stimulant group and 8.87% in 
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dial infarction. A variety of treatment modalities have been used in patients with 
massive PE, which include systemic anticoagulation, catheter-directed thromboly-
sis (CDT) and etc. Methods: A Markov model was constructed to determine the 
costs and benefits of CDT with urokinase and CDT with alteplase. The time horizon 
of the model was lifetime, and a monthly cycle length was adopted. A review of 
the literature was undertaken to identify the primary studies used to populate 
the decision model. Direct medical costs were assessed from the payer perspec-
tive in the Kazakhstan and analyzed using sensitivity analyses. A Monte Carlo 
analysis with 1000 patients was performed to obtain mean. Results: Compared 
with heparin, CDT was associated with a significant reduction of overall mor-
tality. This reduction was not statistically significant after exclusion of studies 
including highrisk PE. However, major hemorrhage and fatal or intracranial bleed-
ing were significantly more frequent among patients receiving CDT. The multi-
way sensitivity analysis showed that CDT was cost-effective only under specific 
scenarios. The expected costs per patient were $1,656 for CDT with urokinase 
and $990 for CDT with alteplase (difference $666). The mean cost-effectiveness 
ratio was $235,950 per CDT with urokinase and $487,229 for CDT with alteplase. 
Probabilistic sensitivity analysis showed that CDT with urokinase was more effec-
tive and less costly (dominant) in 23% of all simulations. ConClusions: The 
analysis showed that CDT might be cost-effective in sub-groups of patients at 
high risk of death from PE. The use of CDT with urokinase for the treatment of 
haemodynamically stable patients with PE was more cost-effective than CDT with 
alteplase in the Kazakhstan. The fact that when using alteplase have a higher risk 
of hemorrhage than with urokinase is also preferences for the use of urokinase 
for CDT.
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miPomersen for treatment of HyPerCHolesteremia: eViDenCe reView 
anD meta analytiC eValuation of ranDomizeD ControlleD trials
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objeCtives: The objective of this investigation was to assess the evidence base 
by performing a systematic review of randomized controlled trials of Mipomersen 
for treatment of hypercholesteremia. Methods: Studies published in English 
language were collated from PubMed and Cochrane databases using validated 
search strategies. Pre-specified inclusion/exclusion were employed to identify 
randomized controlled trials (RCTs), including Mipomersen based therapy. Two 
researchers independently screened the studies and extracted the data. Analysis 
of comparable outcomes was performed using random-effects model to calculate 
summary weighted mean difference (WMD) and 95% CI using statistical software 
R. Results: Nine studies were finally included for data extraction. Overall effect 
size (WMD(95%CI)) were -0.42 (-0.66,-0.18),-0.24 (-0.37,0.12), -44.18 (-52.74,-35.63), 
-55.80 (-77.36,-34.24) and 0.16(-0.01,0.33) for Apo B, VLDL, LDL, Non-HDL, and HDL 
respectively. Mipomersen was associated with a reduction in LDL-C concentrations 
from baseline at the primary efficacy time point. The mean percentage change 
from baseline in LDL-C concentration was significantly greater with Mipomersen 
than with placebo. For the secondary and tertiary outcome measures, percentage 
changes from baseline were significantly greater with Mipomersen than with 
placebo for apo B, total cholesterol, non-HDL-C. Mipomersen treatment also 
resulted in a significant percentage reduction when compared with the placebo 
group for lipoprotein (a) concentration and LDL-C: HDL-C ratio. The most common 
adverse events were injection-site reactions, influenza-like symptoms, patients 
in Mipomersen group, increase in intrahepatic triglyceride content, increased 
ALT concentrations. ConClusions: The findings show that evidence supports 
Mipomersen being safe and effective intervention as an adjunctive drug for low-
ering LDL-C.
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tHe use of low moleCular weiGHt HeParin anD PneumatiC 
ComPression DeVises for DeeP Vein tHromBosis ProPHylaxis in major 
trauma Patients: a ComParatiVe effeCtiVeness analysis
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objeCtives: Since the optimal Venous Thromboembolism (VTE) prophylaxis strat-
egy for trauma patients is unknown, we performed this study to compare the effec-
tiveness of the use of pharmacological thromboprophylaxis such as Low Molecular 
Weight Heparin (LMWH) to the non-pharmacological thromboprophylaxis such as 
pneumatic compression devices (PCDs) in the prevention of Deep Vein Thrombosis 
(DVT) among major trauma patients. Methods: A simplified decision-analysis 
model was established. The outcome measures for this model were the expected 
utilities resulting for each of the comparison categories. Our model compares 
two strategies, LMMW and PCDs. Patients who received LMWH as prophylactic 
approach will then have the chance to either develop DVT or not develop DVT. As 
some patients develop DVT the have four different chances; to die from DVT, survive 
DVT survive DVT but suffer from bleeding complications, or survive DVT but suffer 
from Heparin Induced Thrombocytopenia (HIT). The expected utility then calculated 
based on the terminal node utility and probability of each possible event. On the 
second hand, PCDs patients will either develop DVT or not based on the probabili-
ties. If developed DVT, they might die, survive, suffer bleeding or suffer Local Tissue 
Injury (LTI). If no DVT, they still suffer the same complications but no death due to 
DVT. Results: The LMWH strategy has a bigger expected utility comparing to that 
for PCDs (0.9904 vs. 0.9865). The difference in the expected utility is about 0.0039 
makes the decision to choose the LMWH strategy that provides the highest possible 
utility. In a one-way sensitivity analysis on the probability of DVT with LMWH. PCDs 
are insensitive to this parameter. As the probability of DVT with LMWH below 0.0285 
then LMWH is the effective strategy. PCDs become the effective strategy when the 
probability of DVT with LMWH exceeds 0.0285. ConClusions: When compared 
the mechanical PCDs as thromboprophylaxis with the pharmacological LMWH, 
LMWH is more effective.
the only eHealth component were excluded. Two authors independently screened 
all studies. The quality of each study was also assessed. Results: eHealth is a rap-
idly growing intervention: 40%, 16%, and 5% of studies included were published in 
2014, 2013, and 2012, respectively. Of the included studies, a variety of diseases were 
represented, with most studies focusing on cardiac disease, depression, diabetes, 
and respiratory diseases. 25% of the studies targeted chronic disease in general. A 
majority of studies explored eHealth in monitoring and maintenance of chronic 
disease. Outcomes to assess program efficacy were often measured using changes 
in disease specific outcomes, while few studies provided economic outcomes. Long 
term outcomes were not commonly assessed but implied through surrogate out-
comes. ConClusions: Current evidence suggests that eHealth has the potential 
to help patients and medical professionals better control chronic disease related 
events and decrease rising healthcare costs. However, measurement of long term 
event avoidance and patient quality of life is needed to develop meaningful and 
effective programs and to allocate eHealth appropriately.
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objeCtives: The novel oral anti-coagulants (NOACs) have not been compared 
directly in a randomized controlled trial (RCT) examining the initial treatment of 
venous thromboembolism (VTE). A systematic review and network meta-analysis 
(NMA) were conducted to compare the efficacy and safety of the NOACs in this 
indication. Safety with respect to bleeding is a major concern for physicians and 
patients. Methods: Electronic databases were systematically searched (July 
2014) to identify randomized controlled trials (RCTs) evaluating apixaban, dabi-
gatran, rivaroxaban, and edoxaban versus standard care. Eligible adult patients 
had objectively confirmed deep vein thrombosis (DVT), pulmonary embolism 
(PE) or both. A fixed-effect Bayesian NMA was conducted for relevant out-
comes. Results: Six phase III RCTs were included: apixaban (AMPLIFY [n= 5,395]); 
rivaroxaban (EINSTEIN-DVT/PE pooled [n= 4,832+3449]); dabigatran (RE-COVER I/
II [n= 2,539/2568]); edoxaban (Hokusai-VTE [n= 8,292]). The relative risk of ‘VTE 
and VTE-related death’ was lower with apixaban compared with both dabigatran 
(↓24%, 0.76 [0.46, 1.26]), rivaroxaban (↓7%, 0.93 [0.59, 1.45]) and edoxaban (↓6%, 
0.94 [0.62, 1.42]). Apixaban was associated with the most favorable safety profile, 
showing a statistically significant reduction in the risk of ‘major or clinically rel-
evant non-major (CRNM) bleed’ compared with rivaroxaban (↓53%, 0.47 [0.36, 0.61]), 
dabigatran (↓31%, 0.69 [0.51, 0.94]) and edoxaban (↓46%, 0.69 [0.51, 0.94]). The rela-
tive risks of all-cause mortality for apixaban versus dabigatran, rivaroxaban and 
edoxaban were comparable (21%, 0.79 [0.44, 1.40]; 18%, 0.82 [0.50, 1.34]; 25%, 0.75 
[0.47, 1.21], respectively). ConClusions: While the NOACs have similar efficacy 
in terms of reduction in VTE or VTE-related death, apixaban had a significantly 
better safety profile versus other NOACs in terms of reduction in ‘major or CRNM 
bleed’ for initial/long term treatment of VTE.
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objeCtives: The complexity of therapy and pill burden has a direct impact on 
treatment compliance. Compliance is improved when agents are prescribed as 
fixed dose combinations rather than separate pills. This could be of particular 
value in elderly patients with multiple morbidities requiring polypharmacy. This 
systematic review aims to at evaluating efficacy and safety of the once-daily fixed-
dose-combination (bisoprolol+amlodipine) on SAH. Methods: Electronic searches 
included MEDLINE, LILACS, EMBASE, CRD, among others until June 2014. Search 
terms included “Amlodipine”, “Bisoprolol” and “Hypertension” via MESH controlled 
vocabulary. Where included studies with information on patients using the combi-
nation for hypertension treatment. Two reviewers performed the search. Results: 
From 704 articles found, 3 evaluated efficacy. Mean reduction of 19.7% in DBP, from 
103.9±9.6 mmHg at baseline to 83.4±6.2 mmHg (p< 0.0001). SBP decreased from 
20.4% to 21,8% and DBP decreased19.7% to 21.2%. SBP/DBP goal (< 140/90 mmHg) 
was reached or exceeded from 82.5 to 89.0% of patients by the end of 8 weeks. HR 
presented reductions from 10.4% to 21.65% to the end of 8 weeks (from 87.3 ± 11.07 
bpm to 68.4 ± 8.13 bpm). Pedal edema was observed in 7.5% to 8%. Excellent/good 
tolerability was reported by 90.6% to 94% of patients. Combination therapy is likely 
to cause fewer AEs with lower doses. Benefits of fixed-dose include reduced pill 
burden, improved BP control, compliance and cost savings. Persistence rate of 58.3% 
compared to 14.9% and a compliance rate of 76.9% versus 54.4% were observed. 
Patients with HR > 79 bpm had an 89% greater risk of mortality than those with HR 
≤ 79 bpm. ConClusions: In summary, bisoprolol plus amlodipine in a fixed-dose 
combination showed to improve response rate, with a similar safety profile when 
compared with amlodipine and bisoprolol in monotherapy, potentially leading to 
an increase in SAH treatment compliance.
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effeCtiVeness anD Cost-effeCtiVeness of CatHeter-DireCteD 
tHromBolysis in massiVe Pulmonary emBolism
Kostyuk A.1, Akanov A.2, Garkalov K.1
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objeCtives: Massive pulmonary embolism (PE) is a life-threatening condition 
associated with a high incidence of fatalities comparable to that of acute myocar-
